<![CDATA[The increasing prevalence of multidrug-resistant (MDR) Enterococcus spp. poses a significant public health concern, particularly in Indonesia, where antibiotic misuse is prevalent. This study addresses the urgent need to understand the extent of MDR Enterococcus infections within clinical settings in Semarang, as existing data on this specific issue remains limited. The primary objective of this cross-sectional study was to investigate the prevalence and antimicrobial resistance profiles of MDR Enterococcus spp. isolated from clinical samples in Semarang, Indonesia. A total of 80 clinical samples were collected from patients at the KRMT Wongsonegoro Hospital, Semarang, Indonesia, over three years (January 2022 to December 2024). The identification of Enterococcus spp. was conducted using Gram staining and biochemical assays, followed by antimicrobial susceptibility testing utilizing the VITEK®2 Compact system. Enterococcus spp. was most commonly found in clinical pus (36.3%), and urine (32.5%) clinical samples. Of 80 Enterococcus spp. isolates, 65 (81.25%) were MDR. Above 90% of the 80 isolates were ampicillin and Tigecycline-sensitive. This investigation also found that Enterococcus spp. isolates were resistant to tetracycline (66.3%), erythromycin (77.5%), and Quinupristin/Dalfopristin (86%). Conclusions: The study underscores the critical implications for healthcare providers and policy makers in addressing MDR Enterococcus infections. Enhanced surveillance and tailored antimicrobial stewardship programs are essential to mitigate the risks associated with these infections, ultimately improving patient outcomes and reducing healthcare burdens in Indonesia.]]>
Copyrights © 2026
